Literature DB >> 27155971

Relationship between uterine volume and discontinuation of treatment with levonorgestrel-releasing intrauterine devices in patients with adenomyosis.

Ki Hwan Lee1, Jang Kew Kim1, Min A Lee1, Young Bok Ko1, Jung Bo Yang1, Byung Hun Kang1, Heon Jong Yoo2.   

Abstract

OBJECTIVE: This study is to evaluate the relationship between the uterine volume and the failure of levonorgestrel-releasing intrauterine device (LNG-IUD) in patients with adenomyosis.
METHODS: A total of 171 women with adenomysis were treated with LNG-IUD from November 2009 to December 2011. The amount of menorrhagia, degree of dysmenorrhea, and the uterine volume were compared before and after insertion of LNG-IUD, and the treatment failure of LNG-IUD was observed.
RESULTS: The mean age of the participants was 42.5 years (range 29-53 years). The mean uterine volume was 158 mL (range 46-769 mL). Among the total participants, 37 (21.6 %) discontinued the treatment prematurely. There were no different characteristics between the ongoing treatment group and treatment failure group with LNG-IUD. However, there was significant difference of uterine volume between two groups (178 ± 14 and 141 ± 7 mL, P = 0.010). Based on the receiver operator characteristic analysis, the optimum cutoff value of uterine volume more than 150 mL was significantly associated with failure of LNG-IUD (area under curve: 0.763, 95 % CI 0.669-0.856). In univariate analysis, the uterine volume more than 150 mL was the only independent factor for the failure of LNG-IUD (odds ratio 6.76, 95 % CI 1.20-38.02, P = 0.030).
CONCLUSION: The rate of treatment failure after LNG-IUD insertion for the patients with adenomyosis was related to the uterine volume. Specifically, the treatment failure rate of large volume uterus (>150 mL) with LNG-IUD was significantly higher than that of small volume uterus.

Entities:  

Keywords:  Adenomyosis; Levonorgestrel-releasing intrauterine device; Uterine volume

Mesh:

Substances:

Year:  2016        PMID: 27155971     DOI: 10.1007/s00404-016-4105-y

Source DB:  PubMed          Journal:  Arch Gynecol Obstet        ISSN: 0932-0067            Impact factor:   2.344


  5 in total

1.  [Progress on medical treatment in the management of adenomyosis].

Authors:  Kalianee Devi Baboo; Zhengyun Chen; Xinmei Zhang
Journal:  Zhejiang Da Xue Xue Bao Yi Xue Ban       Date:  2019-04-25

2.  [Efficacy and adverse effects of levonorgestrel-releasing intrauterine system in treatment of adenomyosis].

Authors:  Lifeng Zhang; Hui Yang; Xinmei Zhang; Zhengyun Chen
Journal:  Zhejiang Da Xue Xue Bao Yi Xue Ban       Date:  2019-04-25

3.  Efficacy of the levonorgestrel-releasing intrauterine device is associated with different subtypes of adenomyosis: a retrospective study.

Authors:  Shuyi Chen; Jianzhang Wang; Wenting Sun; Libo Zhu; Jiayi He; Xinmei Zhang
Journal:  Ann Transl Med       Date:  2020-11

4.  Characterization of patients that can continue conservative treatment for adenomyosis.

Authors:  Chiho Miyagawa; Kosuke Murakami; Takako Tobiume; Takafumi Nonogaki; Noriomi Matsumura
Journal:  BMC Womens Health       Date:  2021-12-28       Impact factor: 2.809

Review 5.  Progesterone Actions and Resistance in Gynecological Disorders.

Authors:  James A MacLean; Kanako Hayashi
Journal:  Cells       Date:  2022-02-13       Impact factor: 6.600

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.